Spruce Biosciences Q2 2026: cash $96.3M, TA-ERT BLA on track for Q4, $5.5M investment

SPRUCE BIOSCIENCES, INC.

Cash and equivalents $96.3M at Jun 30, 2026 vs $48.9M at Dec 31, 2025; runway into H2 2027.
Q2 2026 net loss $16.2M ($6.68/share); six-month net loss $28.5M ($14.96/share).
BLA for TA-ERT (MPS IIIB) expected Q4 2026; TrAnsform confirmatory study to initiate Q4 2026.
Cure Sanfilippo Foundation and National MPS Society invest combined $5.5M to fund TA-ERT Expanded Access Program.
Appointed Adrian Quartel, M.D. as CMO (Jul 27, 2026) and Jessica Cohen Pfeffer, M.D. as VP Clinical Development (Aug 3, 2026).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.